Trichomoniasis remains startlingly common, with WHO estimating about 156 million new cases every year worldwide. In the US, women have a 2.1% estimated prevalence overall while risk can jump dramatically by age, race, and sexual health factors, including up to 9.6% among African American women aged 14 to 49. This post pulls together those figures and the diagnostic performance behind them, from NAAT sensitivity to why many infections stay unnoticed.
Key Takeaways
- Trichomoniasis prevalence is highest among women aged 35-49 in US at 3.2%
- African American ethnicity increases risk 5.6-fold compared to whites per NHANES
- Low socioeconomic status correlates with 2-3 times higher prevalence
- NAAT sensitivity 95-99% for vaginal swabs in women
- Wet mount microscopy sensitivity only 51-65% in symptomatic women
- Culture sensitivity 75-85% but 3-7 day turnaround
- Globally, Trichomoniasis affects approximately 156 million new cases annually according to WHO estimates
- In the United States, about 3.7 million people have trichomoniasis, with no more than 30% developing symptoms
- Prevalence among women in the US is estimated at 2.1% based on NHANES data from 2013-2016
- Vaginal symptoms like discharge reported in 10-30% of infected women
- Frothy yellow-green vaginal discharge classic in 20-50% symptomatic cases
- Vulvovaginal itching or irritation in 40-60% of women
- Metronidazole 2g single dose cures 84-98% infections
- Tinidazole 2g single dose efficacy 92-100%
- Metronidazole 500mg BID x7 days 86-92% cure rate
Trichomoniasis affects millions yearly, but key US risk factors and effective NAAT screening drive prevention.
Related reading
01 · Category
Demographics and Risk Factors27 stats
01
Trichomoniasis prevalence is highest among women aged 35-49 in US at 3.2%
02
African American ethnicity increases risk 5.6-fold compared to whites per NHANES
03
Low socioeconomic status correlates with 2-3 times higher prevalence
04
HIV co-infection raises odds ratio to 3.69 for trichomoniasis
05
Multiple lifetime sexual partners (>5) associated with OR 2.1
06
Lack of condom use increases risk by 1.5-2.0 times
07
Older age (>40) in women linked to 1.8 OR for infection
08
Incarceration history elevates risk 4-fold in women
09
Douching practice associated with 1.6 OR
10
Urban residence vs rural OR 1.4 for prevalence
11
Smoking increases risk by 1.3 times in cohort studies
12
History of bacterial vaginosis OR 2.5 for trich
13
Among pregnant women, third trimester highest risk OR 1.7
14
Male circumcision reduces transmission risk by 20-30%
15
Alcohol use disorder OR 1.9 for infection
16
Low education level (<high school) OR 2.2
17
Commercial sex work increases risk 10-fold
18
Obesity (BMI>30) linked to OR 1.4 in women
19
Partner with non-monogamy OR 3.1
20
History of STIs (gonorrhea/chlamydia) OR 2.8
21
Indigenous populations OR 4.5 higher prevalence
22
Illicit drug use OR 2.0
23
Homelessness elevates risk 3-fold
24
Younger age at first sex (<16) OR 1.7
25
Inconsistent PrEP use in MSM OR 1.5 for acquisition
26
Postmenopausal status OR 2.1 due to atrophy
27
Rural African communities OR 2.3 vs urban
Interpretation
Demographics and Risk Factors Interpretation
Trichomoniasis prevalence reveals a stark map of health disparities, where biological factors like age and sex intersect with powerful social determinants—poverty, systemic racism, incarceration, and limited healthcare access—to create overlapping vulnerabilities, proving that this infection is less about individual choices and more about the systemic cracks people fall through.
02 · Category
Diagnosis and Screening28 stats
01
NAAT sensitivity 95-99% for vaginal swabs in women
02
Wet mount microscopy sensitivity only 51-65% in symptomatic women
03
Culture sensitivity 75-85% but 3-7 day turnaround
04
Rapid antigen tests sensitivity 80-90%, specificity 95%
05
Urine NAAT in men sensitivity 85-95%
06
Self-collected vaginal swabs NAAT 98% concordance with clinician
07
Point-of-care OSOM Trich test sensitivity 83%, specificity 97%
08
Multiplex NAAT panels detect trich with 96% sensitivity
09
pH >4.5 in 70% symptomatic vaginal fluid
10
Clue cells absent, distinguishing from BV
11
Motile trichomonads seen in 60% wet prep if symptomatic
12
First-void urine best for men, sensitivity 92%
13
Endocervical swab sensitivity lower 70%
14
FDA-cleared Aptima T. vaginalis assay 95.1% sensitivity
15
Screening recommended for HIV+ women annually
16
Prevalence screening in high-risk clinics detects 5-10% positives
17
Transcription-mediated amplification (TMA) specificity 99.5%
18
Vaginal cup self-collection 94% sensitivity
19
Semen NAAT sensitivity 90% in men
20
Whiff test positive with KOH in 70%
21
Colposcopy strawberry spots pathognomonic 5%
22
PCR sensitivity 98% on vaginal swabs
23
Routine screening not recommended general pop due to low prevalence
24
Male urethral swab NAAT 88% sensitivity
25
Duplex real-time PCR detects resistance markers
26
Screening in pregnancy reduces PTB by 35%
27
Anal swab NAAT in MSM 85% sensitivity
28
Microscopy false negative higher in asymptomatic 30-50%
Interpretation
Diagnosis and Screening Interpretation
We humans have devised a remarkably clever arsenal to spot this tricky parasite, yet ironically, our oldest tool—the microscope—is about as reliable as a coin flip, while a woman's own hand can collect a sample that rivals a clinician's for accuracy.
03 · Category
Prevalence and Incidence30 stats
01
Globally, Trichomoniasis affects approximately 156 million new cases annually according to WHO estimates
02
In the United States, about 3.7 million people have trichomoniasis, with no more than 30% developing symptoms
03
Prevalence among women in the US is estimated at 2.1% based on NHANES data from 2013-2016
04
Among African American women aged 14-49, prevalence reaches 9.6% per NHANES 2013-2016 survey
05
Incidence rate in US women is approximately 1.3% per year from longitudinal studies
06
Global prevalence among women is 5.3-11.1% in high-risk populations per meta-analysis
07
In sub-Saharan Africa, prevalence among pregnant women is 12-30%
08
US men prevalence estimated at 0.5% asymptomatic carriers
09
Among sexually active adolescents in the US, prevalence is 2-3%
10
In HIV-positive women, prevalence is 21-37% higher than general population
11
Annual global incidence estimated at 156 million cases by WHO 2020 data
12
Prevalence in US clinics serving low-income populations up to 13%
13
Among incarcerated women in US, prevalence 25-50%
14
In Latin America, prevalence among women 4-15%
15
US non-Hispanic black women prevalence 13.3 times higher than whites per NHANES
16
Prevalence in Asia-Pacific region 2-10% among antenatal clinic attendees
17
In Europe, prevalence below 1% in general population but up to 10% in STI clinics
18
Among US military personnel, prevalence 2.3% in women
19
Global burden contributes to 10.8% of curable STIs per WHO
20
In Australia, prevalence among women 1.4% from sentinel surveillance
21
Prevalence among MSM in US is 1-2%
22
In South Africa, community prevalence 11% in women aged 15-49
23
US emergency department screening shows 4.4% prevalence in women
24
Prevalence in Canada indigenous women up to 25%
25
In India, prevalence 8.1% among symptomatic women
26
Prevalence among postmenopausal women 4-10%
27
In Brazil, urban slum women prevalence 9.5%
28
US adolescent clinic prevalence 4.2% in females
29
Global asymptomatic rate 70-85% of infections
30
In China, prevalence 1.5-4% in general female population
Interpretation
Prevalence and Incidence Interpretation
While trichomoniasis commands a staggering global audience of 156 million new cases annually, its silent majority—the 70-85% who show no symptoms—serves as a stealthy reminder that this common infection thrives precisely because we don't hear it coming.
04 · Category
Symptoms and Complications30 stats
01
Vaginal symptoms like discharge reported in 10-30% of infected women
02
Frothy yellow-green vaginal discharge classic in 20-50% symptomatic cases
03
Vulvovaginal itching or irritation in 40-60% of women
04
Dysuria (painful urination) occurs in 50% of symptomatic females
05
Dyspareunia (painful intercourse) in 30-40% infected women
06
Lower abdominal pain in 20% of cases
07
Men typically asymptomatic (90%), but may have urethritis in 10%
08
Increased risk of preterm birth OR 1.4 in pregnancy
09
Low birth weight association RR 1.36
10
Posthitis or balanitis in 5-15% symptomatic men
11
Cervicitis signs (strawberry cervix) in 2-5% via colposcopy
12
HIV acquisition risk increased 1.5-2.7 fold in women
13
Pelvic inflammatory disease risk OR 2.0
14
Asymptomatic bacteriuria in 20% pregnant carriers
15
Urethral discharge in men 10-20% mild cases
16
Chronic infection leads to infertility in 10-15% untreated women
17
Vaginitis symptoms persist >1 month in 30% without treatment
18
Neonatal transmission risk 5% during vaginal delivery
19
Prostate involvement in men rare, <1% symptomatic prostatitis
20
Increased cervical cancer risk OR 1.5 via HPV synergy
21
Malodorous discharge noted by 25% patients
22
Postmenopausal spotting in 5-10% carriers
23
Epididymitis rare complication <1% in men
24
Reactive arthritis association rare, case reports only
25
BV co-infection in 40-60% trich cases
26
Yeast vaginitis mimic symptoms in 15% differentials
27
Duration of symptoms average 2-3 weeks untreated
28
HPV persistence increased 2-fold with trich
29
Respiratory symptoms in neonates rare pneumonia
30
Urologic symptoms resolve faster in men post-treatment
Interpretation
Symptoms and Complications Interpretation
Trichomoniasis serves as a masterclass in understatement, as its frequently hidden presence in both men and women belies a profound ability to cause anything from a simple, stubborn discharge to dramatically increasing the risks of preterm birth, HIV acquisition, and infertility, all while quietly collaborating with other pathogens to amplify the chaos.
05 · Category
Treatment and Prevention26 stats
01
Metronidazole 2g single dose cures 84-98% infections
02
Tinidazole 2g single dose efficacy 92-100%
03
Metronidazole 500mg BID x7 days 86-92% cure rate
04
Partner treatment reduces reinfection by 50%
05
Abstinence from sex x7 days post-treatment recommended
06
Resistance to metronidazole 4-10% in US strains
07
Condom use reduces transmission by 80-90% consistently
08
Test-of-cure 3 weeks post-treatment in HIV+
09
High-dose tinidazole 2g x2 days for resistant cases 90% cure
10
Vaccine trials Phase I show 60% immune response
11
Expedited partner therapy (EPT) decreases prevalence 20%
12
Probiotics adjunct reduce recurrence 30%
13
Avoid alcohol 24h post-nitroimidazole to prevent disulfiram reaction
14
Pregnancy: metronidazole safe after first trimester 92% cure
15
Male partners treated even if asymptomatic
16
Recurrence rate 10-20% within 3 months untreated partners
17
HPV vaccination may indirectly reduce trich complications
18
Education campaigns lower incidence 15% in communities
19
Douching avoidance reduces risk 40%
20
Intravaginal boric acid adjunct for recurrent 70% success
21
Annual screening HIV+ prevents 25% complications
22
Paromomycin cream for metronidazole allergy 60-80% effective
23
Contact tracing reduces community prevalence 12%
24
PrEP users screen quarterly for STIs including trich
25
Safe sex counseling adherence 70% post-diagnosis
26
Global control programs aim 90% treatment access by 2030
Interpretation
Treatment and Prevention Interpretation
When it comes to beating trichomoniasis, the game plan is clear: treat yourself and your partner aggressively with the right drugs, swear off sex and alcohol temporarily, lean on condoms forever after, and remember that skipping any of these steps is basically sending a formal invitation for a stubborn encore performance.
Reference
Cite This Report
This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.
APA
Gabrielle Fontaine. (2026, February 13). Trichomoniasis Statistics. Gitnux. https://gitnux.org/trichomoniasis-statistics
MLA
Gabrielle Fontaine. "Trichomoniasis Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/trichomoniasis-statistics.
Chicago
Gabrielle Fontaine. 2026. "Trichomoniasis Statistics." Gitnux. https://gitnux.org/trichomoniasis-statistics.
Sources & references
10 datasets cited across this report · attribution is report-level